⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VOR News
Vor Biopharma Inc. Common Stock
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
VOR
Form 8-K
sec.gov
VOR
Form 8-K
sec.gov
VOR
Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
globenewswire.com
VOR
Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
globenewswire.com
VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
VOR
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
globenewswire.com
VOR
Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
globenewswire.com
VOR
Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
VOR